Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06275-0511US1	Application No. 10/580,576	
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Roger Victor Bonnert et al.		
		Filing Date May 25, 2007	Group Art Unit 1625	

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1	2008-0249110	10/09/2008	Bonnert et al.			
	2	2008-0027092	01/31/2008	Bonnert et al.			
	3	2008-0051586	02/28/2008	Keegan et al.			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner	Desig.	Document	Publication	Country or			Transl	ation
Initial	ID	Number	Date	Patent Office	Class	Subclass	Yes	No
	4	WO 01/032621	05/10/2001	WIPO			Abstract	
	5	WO 2005/019171	03/03/2005	WIPO				
	6	WO 2005/040114	05/06/2005	WIPO				
	7	WO 2005/054232	06/16/2005	WIPO				
	8	WO 2006/075139	07/20/2006	WIPO				
	9	WO 2007/138282	12/06/2007	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)				
Examiner Initial	Desig. ID	Document		
	10	Morissette et al., "High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids", <i>Advanced Drug Delivery Reviews</i> 56:275-300 (2004)		
	11	Patani and LaVoie, "Bioisosterism: A Rational Approach in Drug Design", <i>Chem Rev.</i> 96:3147-3176 (1996)		
	12	Vippagunta et al., abstract, "Crystalline solids", Advanced Drug Delivery Reviews 48:3-26 (2001)		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /PLM/ (09/30/2010)

Examiner Signature /Patricia L. Morris/ (09/30/2010)	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.